Insys Therapeutics, Inc. Releases Statement on Payor Interactions
July 17 2017 - 6:50AM
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”)
issued a statement today on its interactions with payors:
Insys, in concert with its business partners, is
dedicated to helping patients navigate the complex payor
environment that exists for patients as they seek to access the
Insys products that their practicing health care providers have
deemed appropriate or necessary for their treatment. As part
of this endeavor, Insys is committed to establishing long-term
partnerships in the healthcare community with public and private
payors and operating with integrity and ethical standards that
cultivate a culture of trust and transparency.
We believe that in the spirit of accountability, we have taken,
and will continue to take, appropriate steps to learn from the past
and to ensure that appropriate protocols and policies are in place
at our Company. Where appropriate, Insys will vigorously
advocate for fair patient access to medications, as well as
vigorously defend itself within the legal and regulatory
proceedings available to the Company. About INSYS
Insys Therapeutics is a specialty pharmaceutical company that
develops and commercializes innovative drugs and novel drug
delivery systems of therapeutic molecules that improve the quality
of life of patients. Using proprietary sublingual spray technology
and capabilities to develop pharmaceutical cannabinoids, INSYS is
developing a pipeline of products intending to address unmet
medical needs and the clinical shortcomings of existing commercial
products. INSYS currently markets one product, SUBSYS® (fentanyl
sublingual spray) and has received approval for the marketing of
SYNDROS™ (dronabinol oral solution), a proprietary, orally
administered liquid formulation of dronabinol. INSYS is committed
to developing medications for potentially treating addiction to
opioids, opioid overdose, epilepsy, and other disease areas with a
significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development
Company, Inc., a subsidiary of Insys Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property
of their respective owners.
Investor Contact:
Lisa M. Wilson
212-452-2793
E: INSYS@insysrx.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024